Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 16:30 ET | Source: Galecto, Inc.

Galecto Reports First Quarter 2025 Operating and Financial Results

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases,...
March 19, 2025 16:45 ET | Source: Galecto, Inc.

Galecto Reports Full-Year 2024 Financial Results

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets...
February 06, 2025 08:00 ET | Source: Galecto, Inc.

Galecto to Participate in Upcoming Investor Conferences

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases,...
November 01, 2024 08:30 ET | Source: Galecto, Inc.

Galecto Reports Third Quarter 2024 Financial Results

- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets...
October 15, 2024 08:30 ET | Source: Galecto, Inc.

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced...
October 07, 2024 08:45 ET | Source: Galecto, Inc.

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for...
August 28, 2024 09:00 ET | Source: Galecto, Inc.

Galecto Announces Reverse Stock Split

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced...
May 01, 2024 16:01 ET | Source: Galecto, Inc.

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced...
December 21, 2023 16:05 ET | Source: Galecto, Inc.

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
October 23, 2023 08:00 ET | Source: Galecto, Inc.

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented...